140 results on '"Graham SC"'
Search Results
2. 120. Predicting Breast Cancer Related Lymphedema After Immediate Lymphatic Reconstruction:an Artificial Intelligence Approach With Synthetic Data
- Author
-
Berk B. Ozmen, M.D. and Graham Schwarz, M.D.
- Subjects
Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
3. SP47. Artificial Intelligence Based Classification Of ICG Lymphography Patterns
- Author
-
Berk B. Ozmen, M.D., Sonia K. Pandey, M.D., and Graham Schwarz, M.D.
- Subjects
Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
4. Combining experiential knowledge with scholarship in charting the decline of the National Health Service in England
- Author
-
Graham Scambler
- Subjects
auto/biography ,NHS ,neoliberal politics ,funding ,auto-biography ,biography ,Sociology (General) ,HM401-1281 - Abstract
The sustained governmental assault on the National Health Service (NHS) in England during post-1970s financialised or rentier capitalism has received considerable attention by the research community. There is some evidence, however, that many of those members of the public who have not had occasion to use the NHS remain largely ill-informed about the extent of, and reasons for, its present troubles. In this paper I offer an auto/biographic account of my own recent experiences as a patient with type 2 diabetes and subsequent polymyalgia in both primary and secondary care. I then deploy analytic induction to consider, and explain, my personal travails against the background of the shifting nature of doctor-patient interaction occasioned by governmental politics in relation to the NHS. The result is an illustrated story of the decline of health care at a political juncture when the ever-expanding capital assets of a tiny minority of the population trumps the health care needs of the population as a whole. The present impoverishment of management and care must be understood with reference to wider aspects of macro-social change. The paper concludes with some ideas about how to (re)fund a severely ailing NHS.
- Published
- 2023
- Full Text
- View/download PDF
5. Evaluation of Meloidogyne incognita and Rotylenchulus reniformis nematode-resistant cotton cultivars with supplemental Corteva Agriscience nematicides
- Author
-
Kate Turner A., Graham Scott H., Potnis Neha, Brown Steve M., Donald Pat, and Lawrence Kathy S.
- Subjects
cotton ,integrated nematode management ,meloidogyne ,root-knot nematode ,rotylenchulus ,reniform nematode ,Biology (General) ,QH301-705.5 - Abstract
Meloidogyne incognita- and Rotylenchulus reniformis-resistant new cotton cultivars have recently become available, giving growers a new option in nematode management. The objectives of this study were: (i) to determine the yield potential of the new cultivars PHY 360 W3FE (M. incognita-resistant) and PHY 332 W3FE (R. reniformis-resistant) in nematode-infested fields and (ii) to evaluate the effects of combining the nematicides Reklemel (fluazaindolizine), Vydate C-LV (oxamyl), and the seed treatment BIOST Nematicide 100 (heat killed Burkholderia rinojenses and its non-living spent fermentation media) with resistant cotton cultivars on nematode population levels and lint yield. Field experiments in 2020 and 2021 indicated M. incognita population levels were 73% lower on PHY 360 W3FE (R) and 80% lower for R. reniformis on the PHY 332 W3FE (R) at 40 days after planting. Nematode eggs per gram of root were further reduced an average of 86% after the addition of Reklemel and Vydate C-LV when averaging both cultivars over the two years. Tests with BIOST Nematicide 100 + Reklemel + Vydate C-LV (0.56 + 2.5 L/ha) in both M. incognita and R. reniformis fields produced higher lint yields. Overall, planting PHY 360 W3FE (R) and PHY 332 W3FE (R) improved yields an average of 364 kg/ha while limiting nematode population increases. The addition of the nematicides further increased yields 152 kg/ha of the nematode-resistant cultivars.
- Published
- 2023
- Full Text
- View/download PDF
6. Enhancing Microsurgery Outcomes Data with High-Quality Synthetic Data Generated Using Artificial Intelligence: A Proof-of-Concept Study
- Author
-
Berk B. Ozmen, MD and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
7. Predicting Breast Cancer Related Lymphedema after Immediate Lymphatic Reconstruction: An Artificial Intelligence Approach with Synthetic Data
- Author
-
Berk B. Ozmen, MD and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
8. Dual Function of the pUL7-pUL51 Tegument Protein Complex in Herpes Simplex Virus 1 Infection
- Author
-
Albecka, A, Owen, DJ, Ivanova, L, Brun, J, Liman, R, Davies, L, Ahmed, MF, Colaco, S, Hollinshead, M, Graham, SC, Crump, CM, Graham, Stephen [0000-0003-4547-4034], Crump, Colin [0000-0001-9918-9998], and Apollo - University of Cambridge Repository
- Subjects
human herpesviruses ,UL7 ,tegument ,viruses ,UL51 ,focal adhesion ,herpes simplex virus - Abstract
The tegument of herpesviruses is a highly complex structural layer between the nucleocapsid and the envelope of virions. Tegument proteins play both structural and regulatory functions during replication and spread, but the interactions and functions of many of these proteins are poorly understood. Here we focus on two tegument proteins from herpes simplex virus 1 (HSV-1), pUL7 and pUL51, which have homologues in all other herpesviruses. We have now identified that HSV-1 pUL7 and pUL51 form a stable and direct protein-protein interaction, their expression levels rely on the presence of each other, and they function as a complex in infected cells. We demonstrate that expression of the pUL7-pUL51 complex is important for efficient HSV-1 assembly and plaque formation. Furthermore, we also discovered that the pUL7-pUL51 complex localizes to focal adhesions at the plasma membrane in both infected cells and in the absence of other viral proteins. The expression of pUL7-pUL51 is important to stabilize focal adhesions and maintain cell morphology in infected cells and cells infected with viruses lacking pUL7 and/or pUL51 round up more rapidly than cells infected with wild-type HSV-1. Our data suggest that, in addition to the previously reported functions in virus assembly and spread for pUL51, the pUL7-pUL51 complex is important for maintaining the attachment of infected cells to their surroundings through modulating the activity of focal adhesion complexes. $\textbf{IMPORTANCE}$: The $\textit{Herpesviridae }$ is a large family of highly successful human and animal pathogens. Virions of these viruses are composed of many different proteins, most of which are contained within the tegument, a complex structural layer between the nucleocapsid and the envelope within virus particles. Tegument proteins have important roles in assembling virus particles as well as modifying host cells to promote virus replication and spread. However, little is known about the function of many tegument proteins during virus replication. Our study focuses on two tegument proteins from herpes simplex virus 1 that are conserved in all herpesviruses: pUL7 and pUL51. We demonstrate that these proteins directly interact and form a functional complex that is important for both virus assembly and modulation of host cell morphology. Further, we identify for the first time that these conserved herpesvirus tegument proteins localize to focal adhesions in addition to cytoplasmic juxtanuclear membranes within infected cells.
- Published
- 2017
9. Cellular and viral peptides bind multiple sites on the N-terminal domain of clathrin
- Author
-
Muenzner, J, Traub, LM, Kelly, BT, Graham, SC, Graham, Stephen [0000-0003-4547-4034], and Apollo - University of Cambridge Repository
- Subjects
arrestin ,assembly polypeptide 2 (AP2) ,endocytosis ,clathrin-mediated endocytosis ,hepatitis D virus ,amphiphysin - Abstract
Short peptide motifs in unstructured regions of clathrin-adaptor proteins recruit clathrin to membranes to facilitate post-Golgi membrane transport. Three consensus clathrin-binding peptide sequences have been identified and structural studies show that each binds distinct sites on the clathrin heavy chain N-terminal domain (NTD). A fourth binding site for adaptors on NTD has been functionally identified but not structurally characterised. We have solved high resolution structures of NTD bound to peptide motifs from the cellular clathrin adaptors β2 adaptin and amphiphysin plus a putative viral clathrin adaptor, hepatitis D virus large antigen (HDAg-L). Surprisingly, with each peptide we observe simultaneous peptide binding at multiple sites on NTD and viral peptides binding to the same sites as cellular peptides. Peptides containing clathrin-box motifs (CBMs) with the consensus sequence LΦxΦ[DE] bind at the 'arrestin box' on NTD, between β-propeller blades 4 and 5, which had previously been thought to bind a distinct consensus sequence. Further, we structurally define the fourth peptide binding site on NTD, which we term the Royle box. In vitro binding assays show that clathrin is more readily captured by cellular CBMs than by HDAg-L, and site-directed mutagenesis confirms that multiple binding sites on NTD contribute to efficient capture by CBM peptides.
- Published
- 2017
10. Randomised controlled trial comparing the clinical and cost-effectiveness of various washout policies versus no washout policy in preventing catheter associated complications in adults living with long-term catheters: study protocol for the CATHETER II study
- Author
-
Mohamed Abdel-fattah, Diana Johnson, Lynda Constable, Ruth Thomas, Seonaidh Cotton, Sheela Tripathee, David Cooper, Sue Boran, Konstantinos Dimitropoulos, Suzanne Evans, Paraskeve Granitsiotis, Hashim Hashim, Mary Kilonzo, James Larcombe, Paul Little, Sara MacLennan, Peter Murchie, Phyo Kyaw Myint, James N’Dow, John Norrie, Muhammad Imran Omar, Catherine Paterson, Graham Scotland, Nikesh Thiruchelvam, and Graeme MacLennan
- Subjects
Catheter blockage ,Catheter washout solutions ,Catheter maintenance solutions ,Indwelling catheter ,Long-term catheter ,Symptomatic catheter-associated urinary tract infection ,Medicine (General) ,R5-920 - Abstract
Abstract Background Various washout policies are widely used in adults living with long-term catheters (LTC). There is currently insufficient evidence on the benefits and potential harms of prophylactic LTC washout policies in the prevention of blockages and other LTC-related adverse events, such as urinary tract infections. CATHETER II tests the hypothesis that weekly prophylactic LTC washouts (normal saline or citric acid) in addition to standard LTC care reduce the incidence of catheter blockage requiring intervention compared to standard LTC care only in adults living with LTC. Methods CATHETER II is a pragmatic three-arm open multi-centre superiority randomised controlled trial with an internal pilot, economic analysis, and embedded qualitative study. Eligible participants are adults aged ≥ 18 years, who have had a LTC in use for ≥ 28 days, have no plans to discontinue the use of the catheter, are able to undertake the catheter washouts, and complete trial documentation or have a carer able to help them. Participants are identified from general practitioner practices, secondary/tertiary care, community healthcare, care homes, and via public advertising strategies. Participants are randomised 1:1:1 to receive a weekly saline (0.9%) washout in addition to standard LTC care, a weekly citric acid (3.23%) washout in addition to standard LTC care or standard LTC care only. Participants and/or carers will receive training to administer the washouts. Patient-reported outcomes are collected at baseline and for 24 months post-randomisation. The primary clinical outcome is catheter blockage requiring intervention up to 24 months post-randomisation expressed per 1000 catheter days. Secondary outcomes include symptomatic catheter-associated urinary tract infection requiring antibiotics, catheter change, adverse events, NHS/ healthcare use, and impact on quality of life. Discussion This study will guide treatment decision-making and clinical practice guidelines regarding the effectiveness of various prophylactic catheter washout policies in men and women living with LTC. This research has received ethical approval from Wales Research Ethics Committee 6 (19/WA/0015). Trial registration ISRCTN ISRCTN17116445 . Registered prospectively on 06 November 2019
- Published
- 2022
- Full Text
- View/download PDF
11. Structure of a complex of CD47 and the paired receptor SIRP alpha reveals a mechanism for ligand discrimination
- Author
-
Hatherley, D, Graham, SC, Turner, J, Harlos, K, Stuart, DI, and Barclay, AN
- Published
- 2016
12. Modulation of apoptosis and pro-inflammatory signalling by vaccinia virus protein N1
- Author
-
de Motes, M, Samantha, CC, Hongwei, R, Almeida, GMF, Keiran, M, Bahar, MW, Stuart, DI, Grimes, JM, Graham, SC, and Smith, GL
- Published
- 2016
13. A conserved interaction between a C-terminal motif in Norovirus VPg and the HEAT-1 domain of eIF4G is essential for translation initiation
- Author
-
Curry, S, Leen, EN, Sorgeloos, F, Correia, S, Chaudhry, Y, Cannac, F, Pastore, C, Xu, Y, Graham, SC, Matthews, SJ, and Goodfellow, IG
- Subjects
viruses ,food and beverages ,environment and public health - Abstract
Translation initiation is a critical early step in the replication cycle of the positive-sense, single-stranded RNA genome of noroviruses, a major cause of gastroenteritis in humans. Norovirus RNA, which has neither a 5 ́ m7G cap nor an internal ribosome entry site (IRES), adopts an unusual mechanism to initiate protein synthesis that relies on interactions between the VPg protein covalently attached to the 5 ́-end of the viral RNA and eukaryotic initiation factors (eIFs) in the host cell. For murine norovirus (MNV) we previously showed that VPg binds to the middle fragment of eIF4G (4GM; residues 652-1132). Here we have used pull-down assays, fluorescence anisotropy, and isothermal titration calorimetry (ITC) to demonstrate that a stretch of ~20 amino acids at the C terminus of MNV VPg mediates direct and specific binding to the HEAT-1 domain within the 4GM fragment of eIF4G. Our analysis further reveals that the MNV C-terminus binds to eIF4G HEAT-1 via a motif that is conserved in all known noroviruses. Fine mutagenic mapping suggests that the MNV VPg C terminus may interact with eIF4G in a helical conformation. NMR spectroscopy was used to define the VPg binding site on eIF4G HEAT-1, which was confirmed by mutagenesis and binding assays. We have found that this site is non-overlapping with the binding site for eIF4A on eIF4G HEAT-1 by demonstrating that norovirus VPg can form ternary VPg-eIF4G-eIF4A complexes. The functional significance of the VPg-eIF4G interaction was shown by the ability of fusion proteins containing the C- terminal peptide of MNV VPg to inhibit translation of norovirus RNA but not cap- or IRES-dependent translation. These observations define important structural details of a functional interaction between norovirus VPg and eIF4G and reveal a binding interface that might be exploited as a target for antiviral therapy.
- Published
- 2015
14. 39. Safety of Hormonal Therapy Prior to Diep Reconstruction: A Matched Cohort Analysis
- Author
-
Viren Patel, MD, Shannon Wu, BS, Rachel Schafer, BS, Priya Shukla, BS, Anthony Deleonibus, MD, Sarah Bishop, MD, Steven Bernard, MD, Risal Djohan, MD, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2023
- Full Text
- View/download PDF
15. Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury
- Author
-
Elisabet Jacobsen, Simon Sawhney, Miriam Brazzelli, Lorna Aucott, Graham Scotland, Magaly Aceves-Martins, Clare Robertson, Mari Imamura, Amudha Poobalan, Paul Manson, Callum Kaye, and Dwayne Boyers
- Subjects
Acute kidney injury ,Critical care ,Cost-effectiveness ,Diagnostic accuracy ,Economic evaluation ,Markov model ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Early and accurate acute kidney injury (AKI) detection may improve patient outcomes and reduce health service costs. This study evaluates the diagnostic accuracy and cost-effectiveness of NephroCheck and NGAL (urine and plasma) biomarker tests used alongside standard care, compared with standard care to detect AKI in hospitalised UK adults. Methods A 90-day decision tree and lifetime Markov cohort model predicted costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) from a UK NHS perspective. Test accuracy was informed by a meta-analysis of diagnostic accuracy studies. Clinical trial and observational data informed the link between AKI and health outcomes, health state probabilities, costs and utilities. Value of information (VOI) analysis informed future research priorities. Results Under base case assumptions, the biomarker tests were not cost-effective with ICERs of £105,965 (NephroCheck), £539,041 (NGAL urine BioPorto), £633,846 (NGAL plasma BioPorto) and £725,061 (NGAL urine ARCHITECT) per QALY gained compared to standard care. Results were uncertain, due to limited trial data, with probabilities of cost-effectiveness at £20,000 per QALY ranging from 0 to 99% and 0 to 56% for NephroCheck and NGAL tests respectively. The expected value of perfect information (EVPI) was £66 M, which demonstrated that additional research to resolve decision uncertainty is worthwhile. Conclusions Current evidence is inadequate to support the cost-effectiveness of general use of biomarker tests. Future research evaluating the clinical and cost-effectiveness of test guided implementation of protective care bundles is necessary. Improving the evidence base around the impact of tests on AKI staging, and of AKI staging on clinical outcomes would have the greatest impact on reducing decision uncertainty.
- Published
- 2021
- Full Text
- View/download PDF
16. 42. Accessibility of Neurotization in Deep Inferior Epigastric Perforator Flap Reconstruction: A Single Center Analysis
- Author
-
Rachel E. Schafer, BA, Shannon Wu, BS, Priya Shukla, BS, Steven Bernard, MD, Graham Schwarz, MD, Sarah Bishop, MD, Raffi Gurunian, MD, and Risal Djohan, MD
- Subjects
Surgery ,RD1-811 - Published
- 2023
- Full Text
- View/download PDF
17. 57. Safety of Hormonal Therapy Prior to DIEP Reconstruction: A Matched Cohort Analysis
- Author
-
Viren Patel, MD, Shannon Wu, BS, Rachel Schafer, BS, Priya Shukla, BS, Anthony Deleonibus, MD, Sarah Bishop, MD, Raffi Gurunian, MD, Stephen Bernard, MD, Risal Djohan, MD, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2023
- Full Text
- View/download PDF
18. Cost-effectiveness and value of information analysis of multiple frequency bioimpedance devices for fluid management in people with chronic kidney disease having dialysis
- Author
-
Elisabet Jacobsen, Moira Cruickshank, David Cooper, Angharad Marks, Miriam Brazzelli, and Graham Scotland
- Subjects
Multiple frequency bioimpedance devices ,BCM—Body Composition Monitor ,Cost-effectiveness ,Value of information analysis ,Medicine (General) ,R5-920 - Abstract
Abstract Background Among people with chronic kidney disease (CKD) on dialysis, sub-optimal fluid management has been linked with hospitalisation, cardiovascular complications and death. This study assessed the cost-effectiveness using multiple-frequency bioimpedance guided fluid management versus standard fluid management based on clinical judgment. Methods A Markov model was developed to compare expected costs, outcomes and quality adjusted life years of the alternative management strategies. The relative effectiveness of the bioimpedance guided approach was informed by a systematic review of clinical trials, and focussed reviews were conducted to identify baseline event rates, costs and health state utility values for application in the model. The model was analysed probabilistically and a value of information (VOI) analysis was conducted to inform the value of conducting further research to reduce current uncertainties in the evidence base. Results For the base-case analysis, the incremental cost-effectiveness ratio (ICER) for bioimpedance guided fluid management versus standard management was £16,536 per QALY gained. There was a 59% chance of the ICER being below £20,000 per QALY. Form the VOI analysis, the theoretical upper bound on the value of further research was £53 million. The value of further research was highest for parameters relating to the relative effectiveness of bioimpedance guided management on final health outcomes. Conclusions Multiple frequency bioimpedance testing may offer a cost-effective approach to improve fluid management in patients with CKD on dialysis, but further research would be of value to reduce the current uncertainties.
- Published
- 2021
- Full Text
- View/download PDF
19. Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT
- Author
-
Steve Turner, Seonaidh Cotton, Jessica Wood, Victoria Bell, Edwin-Amalraj Raja, Neil W Scott, Heather Morgan, Louisa Lawrie, David Emele, Charlotte Kennedy, Graham Scotland, Shona Fielding, Graeme MacLennan, John Norrie, Mark Forrest, Erol Gaillard, Johan de Jongeste, Marielle Pijnenburg, Mike Thomas, and David Price
- Subjects
child ,asthma ,nitric oxide ,exacerbation ,Medicine - Abstract
Background: The role of fractional exhaled nitric oxide in guiding asthma treatment in children is uncertain. Objective: To compare treatment guided by both fractional exhaled nitric oxide and symptoms (intervention) with treatment guided by symptoms alone (standard care) in children with asthma who are at risk of an asthma exacerbation, in terms of the number of asthma exacerbations over 12 months. Design: This was a pragmatic, multicentre, randomised controlled trial with embedded cost-effectiveness and qualitative process evaluations. Randomisation (1 : 1) was carried out using a remote web-based system and was minimised on recruitment centre, age, sex and British Thoracic Society treatment step. Clinical teams and participants were not blind to treatment allocation. Setting: The trial took place in 35 hospitals and seven primary care practices in the UK. Participants: Children aged 6–15 years with a diagnosis of asthma who were currently prescribed inhaled corticosteroids and who had one or more parent-/patient-reported asthma exacerbation treated with oral corticosteroids in the 12 months prior to recruitment. Interventions: Asthma treatment guided by symptoms alone (standard care) and asthma treatment guided by symptoms plus fractional exhaled nitric oxide (intervention). Treatment recommendations in both groups were protocolised within a web-based algorithm, incorporating inhaled corticosteroid adherence (objectively measured using an electronic logging device) and current treatment. Main outcome measures: The primary outcome measure was asthma exacerbations treated with oral corticosteroids in the year post randomisation. Secondary outcomes included time to first exacerbation, number of exacerbations, lung function, fractional exhaled nitric oxide, daily dose of inhaled corticosteroid, asthma control and quality of life. Results: In total, 509 eligible participants were recruited and the primary outcome was available for 506 participants. The primary outcome occurred in 123 out of 255 (48.2%) participants in the intervention group and 129 out of 251 (51.4%) participants in the standard-care group (adjusted odds ratio 0.88, 95% confidence interval 0.61 to 1.27). There was algorithm non-compliance on 21% of assessments. Per-protocol and complier-average causal effect analysis did not change the interpretation. This non-statistically significant estimate was consistent across predefined subgroups. There were no differences between the groups in secondary outcomes. There were no serious adverse events or deaths. No meaningful differences in health service costs, direct patient costs or indirect costs to society were identified between the groups. The economic evaluation does not provide evidence to support the cost-effectiveness of the intervention. In the qualitative process evaluation, 15 trial staff and six families were interviewed. Overall, their experiences were positive. The intervention was broadly acceptable, with caveats around clinicians using the algorithm recommendation as a guide and wariness around extreme step ups/downs in treatment in the light of contextual factors not being taken into account by the algorithm. Limitations: Potential limitations included the choice of cut-off point to define uncontrolled asthma and the change in fractional exhaled nitric oxide to trigger a change in treatment. Furthermore, the treatment decisions in the two groups may not have been sufficiently different to create a difference in outcomes. Conclusions: The RAACENO (Reducing Asthma Attacks in Children using Exhaled Nitric Oxide) trial findings do not support the routine use of fractional exhaled nitric oxide measurements as part of asthma management in a secondary care setting. The potential for other objective markers to guide asthma management in children needs to be evaluated. Trial registration: This trial was registered as ISRCTN67875351. Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and National Institute for Health and Care Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 9, No. 4. See the NIHR Journals Library website for further project information.
- Published
- 2022
- Full Text
- View/download PDF
20. Transfer of thawed frozen embryo versus fresh embryo to improve the healthy baby rate in women undergoing IVF: the E-Freeze RCT
- Author
-
Abha Maheshwari, Vasha Bari, Jennifer L Bell, Siladitya Bhattacharya, Priya Bhide, Ursula Bowler, Daniel Brison, Tim Child, Huey Yi Chong, Ying Cheong, Christina Cole, Arri Coomarasamy, Rachel Cutting, Fiona Goodgame, Pollyanna Hardy, Haitham Hamoda, Edmund Juszczak, Yacoub Khalaf, Andrew King, Jennifer J Kurinczuk, Stuart Lavery, Clare Lewis-Jones, Louise Linsell, Nick Macklon, Raj Mathur, David Murray, Jyotsna Pundir, Nick Raine-Fenning, Madhurima Rajkohwa, Lynne Robinson, Graham Scotland, Kayleigh Stanbury, and Stephen Troup
- Subjects
frozen embryos ,healthy baby ,live birth ,randomised controlled trial ,pregnancy ,freezing ,cost-benefit analysis ,embryo transfer ,ovarian hyperstimulation syndrome ,fertilisation in vitro ,Medical technology ,R855-855.5 - Abstract
Background: Freezing all embryos, followed by thawing and transferring them into the uterine cavity at a later stage (freeze-all), instead of fresh-embryo transfer may lead to improved pregnancy rates and fewer complications during in vitro fertilisation and pregnancies resulting from it. Objective: We aimed to evaluate if a policy of freeze-all results in a higher healthy baby rate than the current policy of transferring fresh embryos. Design: This was a pragmatic, multicentre, two-arm, parallel-group, non-blinded, randomised controlled trial. Setting: Eighteen in vitro fertilisation clinics across the UK participated from February 2016 to April 2019. Participants: Couples undergoing their first, second or third cycle of in vitro fertilisation treatment in which the female partner was aged
- Published
- 2022
- Full Text
- View/download PDF
21. Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
- Author
-
Moira Cruickshank, Mari Imamura, Corinne Booth, Lorna Aucott, Carl Counsell, Paul Manson, Graham Scotland, and Miriam Brazzelli
- Subjects
status epilepticus ,benzodiazepines ,antiepileptic drugs ,pre hospital ,review ,economic evaluation ,Medical technology ,R855-855.5 - Abstract
Background: Convulsive status epilepticus is defined as ≥ 5 minutes of either continuous seizure activity or repetitive seizures without regaining consciousness. It is regarded as an emergency condition that requires prompt treatment to avoid hospitalisation and to reduce morbidity and mortality. Rapid pre-hospital first-line treatment of convulsive status epilepticus is currently benzodiazepines, administered either by trained caregivers in the community (e.g. buccal midazolam, rectal diazepam) or by trained health professionals via intramuscular or intravenous routes (e.g. midazolam, lorazepam). There is a lack of clarity about the optimal treatment for convulsive status epilepticus in the pre-hospital setting. Objectives: To assess the current evidence on the clinical effectiveness and cost-effectiveness of treatments for adults with convulsive status epilepticus in the pre-hospital setting. Data sources: We searched major electronic databases, including MEDLINE, EMBASE, PsycInfo®, CINAHL, CENTRAL, NHS Economic Evaluation Database, Health Technology Assessment Database, Research Papers in Economics, and the ISPOR Scientific Presentations Database, with no restrictions on publication date or language of publication. Final searches were carried out on 21 July 2020. Review methods: Systematic review of randomised controlled trials assessing adults with convulsive status epilepticus who received treatment before or on arrival at the emergency department. Eligible treatments were any antiepileptic drugs offered as first-line treatments, regardless of their route of administration. Primary outcomes were seizure cessation, seizure recurrence and adverse events. Two reviewers independently screened all citations identified by the search strategy, retrieved full-text articles, extracted data and assessed the risk of bias of the included trials. Results were described narratively. Results: Four trials (1345 randomised participants, of whom 1234 were adults) assessed the intravenous or intramuscular use of benzodiazepines or other antiepileptic drugs for the pre-hospital treatment of convulsive status epilepticus in adults. Three trials at a low risk of bias showed that benzodiazepines were effective in stopping seizures. In particular, intramuscular midazolam was non-inferior to intravenous lorazepam. The addition of levetiracetam to clonazepam did not show clear advantages over clonazepam alone. One trial at a high risk of bias showed that phenobarbital plus optional phenytoin was more effective in terminating seizures than diazepam plus phenytoin. The median time to seizure cessation from drug administration varied from 1.6 minutes to 15 minutes. The proportion of people with recurrence of seizures ranged from 10.4% to 19.1% in two trials reporting this outcome. Across trials, the rates of respiratory depression among participants receiving active treatments were generally low (from 6.4% to 10.6%). The mortality rate ranged from 2% to 7.6% in active treatment groups and from 6.2% to 15.5% in control groups. Only one study based on retrospective observational data met the criteria for economic evaluation; therefore, it was not possible to draw any robust conclusions on cost-effectiveness. Limitations: The limited number of identified trials and their differences in terms of treatment comparisons and outcomes hindered any meaningful pooling of data. None of the included trials was conducted in the UK and none assessed the use of buccal midazolam or rectal diazepam. The review of economic evaluations was hampered by lack of suitable data. Conclusions: Both intravenous lorazepam and intravenous diazepam administered by paramedics are more effective than a placebo in the treatments of adults with convulsive status epilepticus, and intramuscular midazolam is non-inferior to intravenous lorazepam. Large well-designed clinical trials are needed to establish which benzodiazepines are more effective and preferable in the pre-hospital setting. Study registration: This study is registered as PROSPERO CRD42020201953. Funding: This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis programme and will be published in full in Health Technology Assessment; Vol. 26, No. 20. See the NIHR Journals Library website for further project information.
- Published
- 2022
- Full Text
- View/download PDF
22. Let’s Campaign for a Fairer Society in the Aftermath of COVID-19
- Author
-
Graham Scambler
- Subjects
austerity ,rentier capitalism ,COVID-19 ,fairness ,sociology ,good society ,Sociology (General) ,HM401-1281 - Abstract
In this paper I ground a brief account of the impact of COVID-19 on the United Kingdom in an understanding of a decade of austerity politics from 2010 to 2020, itself a product of the advent and consolidation of post-1970s financialised or rentier capitalism. I argue that such an analysis is essential if realistic plans are to be laid for a “better”—understood here as a more equitable or “fairer”—society. I go on to consider the contributions that sociology can, and arguably should, make to this end. This involves a range of engagements from scholarship at one end of the spectrum to action or muckraking sociology at the other. In addition to plotting a role for sociology, I suggest a set of criteria for recognizing a “fairer society”; postulate a series of institutional reforms that might characterize the attainment of such a society; and outline and confront social structural, cultural and agential obstacles to its realization. A theme running throughout the paper is that the delineation and promulgation of the “good society” remains central to any credible—that is, post-Enlightenment reconstruction of - the sociological project.
- Published
- 2022
- Full Text
- View/download PDF
23. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
- Author
-
Miriam Brazzelli, Lorna Aucott, Magaly Aceves-Martins, Clare Robertson, Elisabet Jacobsen, Mari Imamura, Amudha Poobalan, Paul Manson, Graham Scotland, Callum Kaye, Simon Sawhney, and Dwayne Boyers
- Subjects
biomarkers ,acute kidney injury ,diagnosis ,prediction ,Medical technology ,R855-855.5 - Abstract
Background: Acute kidney injury is a serious complication that occurs in the context of an acute critical illness or during a postoperative period. Earlier detection of acute kidney injury may facilitate strategies to preserve renal function, prevent further disease progression and reduce mortality. Acute kidney injury diagnosis relies on a rise in serum creatinine levels and/or fall in urine output; however, creatinine is an imperfect marker of kidney function. There is interest in the performance of novel biomarkers used in conjunction with existing clinical assessment, such as NephroCheck® (Astute Medical, Inc., San Diego, CA, USA), ARCHITECT® urine neutrophil gelatinase-associated lipocalin (NGAL) (Abbott Laboratories, Abbott Park, IL, USA), and urine and plasma BioPorto NGAL (BioPorto Diagnostics A/S, Hellerup, Denmark) immunoassays. If reliable, these biomarkers may enable earlier identification of acute kidney injury and enhance management of those with a modifiable disease course. Objective: The objective was to evaluate the role of biomarkers for assessing acute kidney injury in critically ill patients who are considered for admission to critical care. Data sources: Major electronic databases, conference abstracts and ongoing studies were searched up to June 2019, with no date restrictions. MEDLINE, EMBASE, Health Technology Assessment Database, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, Web of Science, World Health Organization Global Index Medicus, EU Clinical Trials Register, International Clinical Trials Registry Platform and ClinicalTrials.gov were searched. Review methods: A systematic review and meta-analysis were conducted to evaluate the performance of novel biomarkers for the detection of acute kidney injury and prediction of other relevant clinical outcomes. Random-effects models were adopted to combine evidence. A decision tree was developed to evaluate costs and quality-adjusted life-years accrued as a result of changes in short-term outcomes (up to 90 days), and a Markov model was used to extrapolate results over a lifetime time horizon. Results: A total of 56 studies (17,967 participants), mainly prospective cohort studies, were selected for inclusion. No studies addressing the clinical impact of the use of biomarkers on patient outcomes, compared with standard care, were identified. The main sources of bias across studies were a lack of information on blinding and the optimal threshold for NGAL. For prediction studies, the reporting of statistical details was limited. Although the meta-analyses results showed the potential ability of these biomarkers to detect and predict acute kidney injury, there were limited data to establish any causal link with longer-term health outcomes and there were considerable clinical differences across studies. Cost-effectiveness results were highly uncertain, largely speculative and should be interpreted with caution in the light of the limited evidence base. To illustrate the current uncertainty, 15 scenario analyses were undertaken. Incremental quality-adjusted life-years were very low across all scenarios, ranging from positive to negative increments. Incremental costs were also small, in general, with some scenarios generating cost savings with tests dominant over standard care (cost savings with quality-adjusted life-year gains). However, other scenarios generated results whereby the candidate tests were more costly with fewer quality-adjusted life-years, and were thus dominated by standard care. Therefore, it was not possible to determine a plausible base-case incremental cost-effectiveness ratio for the tests, compared with standard care. Limitations: Clinical effectiveness and cost-effectiveness results were hampered by the considerable heterogeneity across identified studies. Economic model predictions should also be interpreted cautiously because of the unknown impact of NGAL-guided treatment, and uncertain causal links between changes in acute kidney injury status and changes in health outcomes. Conclusions: Current evidence is insufficient to make a full appraisal of the role and economic value of these biomarkers and to determine whether or not they provide cost-effective improvements in the clinical outcomes of acute kidney injury patients. Future work: Future studies should evaluate the targeted use of biomarkers among specific patient populations and the clinical impact of their routine use on patient outcomes and management. Study registration: This study is registered as PROSPERO CRD42019147039. Funding: This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis programme and will be published in full in Health Technology Assessment; Vol. 26, No. 7. See the NIHR Journals Library website for further project information.
- Published
- 2022
- Full Text
- View/download PDF
24. Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study
- Author
-
Katie Banister, Jonathan A Cook, Graham Scotland, Augusto Azuara-Blanco, Beatriz Goulão, Heinrich Heimann, Rodolfo Hernández, Ruth Hogg, Charlotte Kennedy, Sobha Sivaprasad, Craig Ramsay, and Usha Chakravarthy
- Subjects
wet macular degeneration ,sensitivity and specificity ,diagnostic tests, routine ,cost-benefit analysis ,risk factors ,fluorescein angiography ,tomography, optical coherence ,visual acuity ,self-report visual function ,amsler ,quality-adjusted life-years ,adult ,humans ,choroid ,retina ,Medical technology ,R855-855.5 - Abstract
Background: Neovascular age-related macular degeneration is a leading cause of sight loss, and early detection and treatment is important. For patients with neovascular age-related macular degeneration in one eye, it is usual practice to monitor the unaffected eye. The test used to diagnose neovascular age-related macular degeneration, fundus fluorescein angiography, is an invasive test. Non-invasive tests are available, but their diagnostic accuracy is unclear. Objectives: The primary objective was to determine the diagnostic monitoring performance of tests for neovascular age-related macular degeneration in the second eye of patients with unilateral neovascular age-related macular degeneration. The secondary objectives were the cost-effectiveness of tests and to identify predictive factors of developing neovascular age-related macular degeneration. Design: This was a multicentre, prospective, cohort, comparative diagnostic accuracy study in a monitoring setting for up to 3 years. A Cox regression risk prediction model and a Markov microsimulation model comparing cost-effectiveness of the index tests over 25 years were used. Setting: This took place in hospital eye services. Participants: Participants were adults (aged 50–95 years) with newly diagnosed (within the previous 6 weeks) neovascular age-related macular degeneration in one eye and an unaffected second (study) eye who were attending for treatment injections in the first eye and who had a study eye baseline visual acuity of ≥ 68 Early Treatment Diabetic Retinopathy Study letters. Interventions: The index tests were Amsler chart (completed by participants), fundus clinical examination, optical coherence tomography, self-reported vision assessment (completed by participants) and visual acuity. The reference standard was fundus fluorescein angiography. Main outcome measures: The main outcome measures were sensitivity and specificity; the performance of the risk predictor model; and costs and quality-adjusted life-years. Results: In total, 552 out of 578 patients who consented from 24 NHS hospitals (n = 16 ineligible; n = 10 withdrew consent) took part. The mean age of the patients was 77.4 years (standard deviation 7.7 years) and 57.2% were female. For the primary analysis, 464 patients underwent follow-up fundus fluorescein angiography and 120 developed neovascular age-related macular degeneration on fundus fluorescein angiography. The diagnostic accuracy [sensitivity (%) (95% confidence interval); specificity (%) (95% confidence interval)] was as follows: optical coherence tomography 91.7 (85.2 to 95.6); 87.8 (83.8 to 90.9)], fundus clinical examination [53.8 (44.8 to 62.5); 97.6 (95.3 to 98.9)], Amsler [33.7 (25.1 to 43.5); 81.4 (76.4 to 85.5)], visual acuity [30.0 (22.5 to 38.7); 66.3 (61.0 to 71.1)] and self-reported vision [4.2 (1.6 to 9.8); 97.0 (94.6 to 98.5)]. Optical coherence tomography had the highest sensitivity across all secondary analyses. The final prediction model for neovascular age-related macular degeneration in the non-affected eye included smoking status, family history of neovascular age-related macular degeneration, the presence of nodular drusen with or without reticular pseudodrusen, and the presence of pigmentary abnormalities [c-statistic 0.66 (95% confidence interval 0.62 to 0.71)]. Optical coherence tomography monitoring generated the greatest quality-adjusted life-years gained per patient (optical coherence tomography, 5.830; fundus clinical examination, 5.787; Amsler chart, 5.736, self-reported vision, 5.630; and visual acuity, 5.600) for the lowest health-care and social care costs (optical coherence tomography, £19,406; fundus clinical examination, £19,649; Amsler chart, £19,751; self-reported vision, £20,198; and visual acuity, £20,444) over the lifetime of the simulated cohort. Optical coherence tomography dominated the other tests or had an incremental cost-effectiveness ratio below the accepted cost-effectiveness thresholds (£20,000) across the scenarios explored. Limitations: The diagnostic performance may be different in an unselected population without any history of neovascular age-related macular degeneration; the prediction model did not include genetic profile data, which might have improved the discriminatory performance. Conclusions: Optical coherence tomography was the most accurate in diagnosing conversion to neovascular age-related macular degeneration in the fellow eye of patients with unilateral neovascular age-related macular degeneration. Economic modelling suggests that optical coherence tomography monitoring is cost-effective and leads to earlier diagnosis of and treatment for neovascular age-related macular degeneration in the second eye of patients being treated for neovascular age-related macular degeneration in their first eye. Future work: Future works should investigate the role of home monitoring, improved risk prediction models and impact on long-term visual outcomes. Study registration: This study was registered as ISRCTN48855678. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 8. See the NIHR Journals Library website for further project information.
- Published
- 2022
- Full Text
- View/download PDF
25. Assessment of Adverse Event Risk in Combined Plastic Surgery Procedures Utilizing the Tracking Operations and Outcomes for Plastic Surgeons (TOPS) Database
- Author
-
Rachel Schafer, Madeleine Blazel, Amy Nowacki, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2022
- Full Text
- View/download PDF
26. Agreement and Reliability of Parental Reports and Direct Screening of Developmental Outcomes in Toddlers at Risk
- Author
-
Juan Giraldo-Huertas and Graham Schafer
- Subjects
parental reports ,developmental screening ,children at risk ,reliability and agreement studies ,low-middle income countries ,receiver operating characteristic (ROC) analysis ,Psychology ,BF1-990 - Abstract
Developmental screening is a practice that directly benefits vulnerable and low-income families and children when it is regular and frequently applied. A developmental screening tool administered by parents called CARE is tested. CARE contains a compilation of activities to report and enhance development at home. Hundred and fifty-seven families in Bogotá (Colombia) initially responded to a call to participate in developmental screening tools’ validation and reliability study. All children (Average: 42.7 months old; SD: 9.4; Min: 24, Max: 58) were screened directly by trained applicants using a Spanish version of the Denver Developmental Screening test [i.e., the Haizea-Llevant (HLL) screening table]. After a first screening, 61 dyads were positive for follow-up and received a second HLL screening. Fifty-two out of 61 dyads use and returned CARE booklet after 1-month screening at home. The comparative analysis for parent reports using CARE and direct screening observation included (a) the effects of demographic variables on overall and agreement, (b) agreement and congruence between the CARE report classification and direct screening classification (“At risk” or “Not at risk”), (c) receiver operating characteristic analysis, (d) item-Level agreement for specific developmental domains, and (e) acceptability and feasibility analysis. Results and conclusions show the parental report using the CARE booklet as a reliable screening tool that has the potential to activate alerts for an early cognitive delay that reassure clinicians and families to further specialized and controlled developmental evaluations and act as a screen for the presence of such delay in four developmental dimensions.
- Published
- 2021
- Full Text
- View/download PDF
27. Study protocol: E-freeze - freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation
- Author
-
Abha Maheshwari, Siladitya Bhattacharya, Ursula Bowler, Daniel Brison, Tim Child, Christina Cole, Arri Coomarasamy, Rachel Cutting, Stephen Harbottle, Pollyanna Hardy, Edmund Juszczak, Yacoub Khalaf, Jennifer J. Kurinczuk, Stuart Lavery, Clare Lewis-Jones, Nick Macklon, Nick J. Raine-Fenning, Madhurima Rajkohwa, Graham Scotland, and Stephen Troup
- Subjects
IVF ,Fertility ,Frozen thawed embryo transfer ,Fresh embryo transfer ,OHSS ,Elective freezing ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background Infertility affects one in seven couples; many of these need in vitro fertilisation (IVF). IVF involves external hormones to stimulate a woman’s ovaries to produce eggs which are harvested surgically. Embryos, created in the laboratory by mixing eggs with sperm, are grown in culture for a few days before being replaced within the uterus (fresh embryo transfer). Spare embryos are usually frozen with a view to transfer at a later point in time – especially if the initial fresh transfer does not result in a pregnancy. Despite improvements in technology, IVF success rates remain low with an overall live birth rate of 25–30% per treatment. Additionally, there are concerns about health outcomes for mothers and babies conceived through IVF, particularly after fresh embryo transfer, including maternal ovarian hyperstimulation syndrome (OHSS) and preterm delivery. It is believed that high levels of hormones during ovarian stimulation could create a relatively hostile environment for embryo implantation whilst increasing the risk of OHSS. It has been suggested that freezing all embryos with the intention of thawing and replacing them within the uterus at a later stage (thawed frozen embryo transfer) instead of fresh embryo transfer, may lead to improved pregnancy rates and fewer complications. We aim to compare the clinical and cost effectiveness of fresh and thawed frozen embryo transfer, with the primary aim of identifying any difference in the chance of having a healthy baby. Methods E-Freeze is a pragmatic, multicentre two-arm parallel group randomised controlled trial where women aged ≥18 and
- Published
- 2019
- Full Text
- View/download PDF
28. Cost-utility Analysis of Surgical Treatments for Breast Cancer-related Lymphedema
- Author
-
Jessica Yu, BS, Morgan Fish, MD, Yida Cai, MD, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2021
- Full Text
- View/download PDF
29. 42. Assessment of Adverse Event Risk in Combined Plastic Surgery Procedures Utilizing the Tracking Operations and Outcomes for Plastic Surgeons (TOPS) Database
- Author
-
Rachel Schafer, BA, Amy Nowacki, PhD, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2022
- Full Text
- View/download PDF
30. P122. LYMPHATICOVENOUS ANASTOMOSIS DOES NOT INCREASE RECURRENCE RISK IN MELANOMA
- Author
-
Thomas Y. Xia, BS, Cagri Cakmakoglu, MD, Grzegorz Kwiecien, MD, Graham Schwarz, MD, and Brian Gastman, MD
- Subjects
Surgery ,RD1-811 - Published
- 2022
- Full Text
- View/download PDF
31. Nitroglycerin for treatment of retained placenta: A randomised, placebo-controlled, multicentre, double-blind trial in the UK.
- Author
-
Fiona C Denison, Kathryn F Carruthers, Jemma Hudson, Gladys McPherson, Gin Nie Chua, Mathilde Peace, Jane Brewin, Nina Hallowell, Graham Scotland, Julia Lawton, John Norrie, Jane E Norman, and GOT-IT investigator team
- Subjects
Medicine - Abstract
BackgroundRetained placenta following vaginal delivery is a major cause of postpartum haemorrhage. Currently, the only effective treatments for a retained placenta are the surgical procedures of manual removal of placenta (MROP) and uterine curettage, which are not universally available, particularly in low- and middle-income countries. The objective of the trial was to determine whether sublingual nitroglycerin spray was clinically effective and cost-effective for medical treatment of retained placenta following vaginal delivery.Methods and findingsA randomised, placebo-controlled, double-blind trial was undertaken between October 2014 and July 2017 at 29 delivery units in the UK (Edinburgh, Glasgow, Manchester, Newcastle, Preston, Warrington, Chesterfield, Crewe, Durham, West Middlesex, Aylesbury, Furness, Southampton, Bolton, Sunderland, Oxford, Nottingham [2 units], Burnley, Chertsey, Stockton-on-Tees, Middlesborough, Chester, Darlington, York, Reading, Milton Keynes, Telford, Frimley). In total, 1,107 women with retained placenta following vaginal delivery were recruited. The intervention was self-administered 2 puffs of sublingual nitroglycerin (800 μg; intervention, N = 543) or placebo spray (control, N = 564). The primary clinical outcome was the need for MROP, assessed at 15 minutes following administration of the intervention. Analysis was based on the intention-to-treat principle. The primary safety outcome was measured blood loss between study drug administration and transfer to the postnatal ward or other clinical area. The primary patient-sided outcomes were satisfaction with treatment and side-effect profile, assessed by questionnaires pre-discharge and 6 weeks post-delivery. Secondary clinical outcomes were measured at 5 and 15 minutes after study drug administration and prior to hospital discharge. There was no statistically significant or clinically meaningful difference in need for MROP by 15 minutes (primary clinical outcome, 505 [93.3%] for nitroglycerin versus 518 [92.0%] for placebo, odds ratio [OR] 1.01 [95% CI 0.98-1.04], p = 0.393) or blood loss (1,000 ml: nitroglycerin, 119 [22.2%], versus placebo, 87 [15.5%]; ordinal OR 1.14 [95% CI 0.88-1.48], p = 0.314) or satisfaction with treatment (nitroglycerin, 288 [75.4%], versus placebo, 303 [78.1%]; OR 0.87 [95% CI 0.62-1.22], p = 0.411) or health service costs (mean difference [£] 55.3 [95% CI -199.20 to 309.79]). Palpitations following drug administration were reported more often in the nitroglycerin group (36 [9.8%] versus 15 [4.0%], OR 2.60 [95% CI 1.40-4.84], p = 0.003). There were 52 serious adverse events during the trial, with no statistically significant difference in likelihood between groups (nitroglycerin, 27 [5.0%], versus placebo, 26 [4.6%]; OR 1.13 [95% CI 0.54-2.38], p = 0.747). The main limitation of our study was the low return rate for the 6-week postnatal questionnaire. There were, however, no differences in questionnaire return rates between study groups or between women who did and did not have MROP, with the patient-reported use of outpatient and primary care services at 6 weeks accounting for only a small proportion (approximately 5%) of overall health service costs.ConclusionsIn this study, we found that nitroglycerin is neither clinically effective nor cost-effective as a medical treatment for retained placenta, and has increased side effects, suggesting it should not be used. Further research is required to identify an effective medical treatment for retained placenta to reduce the morbidity caused by this condition, particularly in low- and middle-income countries where surgical management is not available.Trial registrationISRCTN.com ISRCTN88609453 ClinicalTrials.gov NCT02085213.
- Published
- 2019
- Full Text
- View/download PDF
32. Glyceryl trinitrate to reduce the need for manual removal of retained placenta following vaginal delivery: the GOT-IT RCT
- Author
-
Fiona C Denison, Kathryn F Carruthers, Jemma Hudson, Gladys McPherson, Graham Scotland, Sheonagh Brook-Smith, Cynthia Clarkson, Mathilde Peace, Jane Brewin, Gin Nie Chua, Nina Hallowell, Jane E Norman, Julia Lawton, and John Norrie
- Subjects
retained placenta ,glyceryl trinitrate ,Medical technology ,R855-855.5 - Abstract
Background: Retained placenta is associated with postpartum haemorrhage and can lead to significant maternal morbidity if untreated. The only effective treatment is the surgical procedure of manual removal of placenta, which is costly, requires skilled staff, requires an operative environment and is unpleasant for women. Small studies suggest that glyceryl trinitrate may be an effective medical alternative. Objective: To determine the clinical effectiveness and cost-effectiveness of sublingual glyceryl trinitrate spray compared with placebo in reducing the need for manual removal of placenta in women with retained placenta after vaginal delivery following the failure of current management. Design: A group-sequential randomised double-blind placebo-controlled trial with a cost-effectiveness analysis. Setting: There were 29 obstetric units in the UK involved in the study. Participants: There were 1107 women (glyceryl trinitrate group, n = 543; placebo group, n = 564) randomised between October 2014 and July 2017. Interventions: Glyceryl trinitrate spray was administered to 541 women in the intervention group, and a placebo was administered to 563 women in the control group. Main outcome measures: Four primary outcomes were defined: (1) clinical – the need for manual removal of placenta, (2) safety – measured blood loss, (3) patient sided – satisfaction with treatment and side effects and (4) economic – cost-effectiveness of both treatments using the UK NHS perspective. Secondary clinical outcomes included a > 15% decrease in haemoglobin level, time from randomisation to delivery of placenta in theatre, the need for earlier manual removal of placenta than planned, increase in heart rate or decrease in blood pressure, requirement for blood transfusion, requirement for general anaesthesia, maternal pyrexia, and sustained uterine relaxation requiring additional uterotonics. Results: No difference was observed between the glyceryl trinitrate group and the control group for the placenta remaining undelivered within 15 minutes of study treatment (93.3% vs. 92%; odds ratio 1.01, 95% confidence interval 0.98 to 1.04; p = 0.393). There was no difference in blood loss of > 1000 ml between the glyceryl trinitrate group and the control group (22.2% vs. 15.5%; odds ratio 1.14, 95% confidence interval 0.88 to 1.48; p = 0.314). Palpitations were more common in the glyceryl trinitrate group than in the control group after taking the study drug (9.8% vs. 4.0%; odds ratio 2.60, 95% confidence interval 1.40 to 4.84; p = 0.003). There was no difference in any other measures of patient satisfaction between the groups. There was no difference in costs to the health service between groups (mean difference £55.30, 95% confidence interval –£199.20 to £309.79). Secondary outcomes revealed that a fall in systolic or diastolic blood pressure, or an increase in heart rate, was more common in the glyceryl trinitrate group than in the control group (odds ratio 4.9, 95% confidence interval 3.7 to 6.4; p
- Published
- 2019
- Full Text
- View/download PDF
33. HEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial
- Author
-
Kevin Cooper, Kirsty McCormack, Suzanne Breeman, Jessica Wood, Neil W. Scott, Justin Clark, Jed Hawe, Robert Hawthorn, Kevin Phillips, Angela Hyde, Alison McDonald, Mark Forrest, Samantha Wileman, Graham Scotland, John Norrie, Siladitya Bhattacharya, and for the HEALTH Study Group
- Subjects
Heavy menstrual bleeding ,Laparoscopic ,Hysterectomy ,Endometrial ablation techniques ,Randomised controlled trial ,Medicine (General) ,R5-920 - Abstract
Abstract Background Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy, i.e. surgical removal of the uterus. While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other pelvic structures. The procedure can be simplified and complications minimised by undertaking a ‘supracervical’ hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which can be performed as a day-case procedure and is relatively easy for the surgeon to learn. HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question ‘Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?’ Methods/Design Women aged
- Published
- 2018
- Full Text
- View/download PDF
34. Laparoscopic supracervical hysterectomy compared with second-generation endometrial ablation for heavy menstrual bleeding: the HEALTH RCT
- Author
-
Kevin Cooper, Suzanne Breeman, Neil W Scott, Graham Scotland, Rodolfo Hernández, T Justin Clark, Jed Hawe, Robert Hawthorn, Kevin Phillips, Samantha Wileman, Kirsty McCormack, John Norrie, and Siladitya Bhattacharya
- Subjects
MENORRHAGIA ,ENDOMETRIAL ABLATION TECHNIQUES ,HYSTERECTOMY ,PATIENT SATISFACTION ,RANDOMISED CONTROLLED TRIAL ,Medical technology ,R855-855.5 - Abstract
Background: Heavy menstrual bleeding (HMB) is a common problem that affects many British women. When initial medical treatment is unsuccessful, the National Institute for Health and Care Excellence recommends surgical options such as endometrial ablation (EA) or hysterectomy. Although clinically and economically more effective than EA, total hysterectomy necessitates a longer hospital stay and is associated with slower recovery and a higher risk of complications. Improvements in endoscopic equipment and training have made laparoscopic supracervical hysterectomy (LASH) accessible to most gynaecologists. This operation could preserve the advantages of total hysterectomy and reduce the risk of complications. Objectives: To compare the clinical effectiveness and cost-effectiveness of LASH with second-generation EA in women with HMB. Design: A parallel-group, multicentre, randomised controlled trial. Allocation was by remote web-based randomisation (1 : 1 ratio). Surgeons and participants were not blinded to the allocated procedure. Setting: Thirty-one UK secondary and tertiary hospitals. Participants: Women aged 11 cm; any fibroids > 3 cm; contraindications to laparoscopic surgery; previous EA; and inability to give informed consent or complete trial paperwork. Interventions: LASH compared with second-generation EA. Main outcome measures: Co-primary clinical outcome measures were (1) patient satisfaction and (2) Menorrhagia Multi-Attribute Quality-of-Life Scale (MMAS) score at 15 months post randomisation. The primary economic outcome was incremental cost (NHS perspective) per quality-adjusted life-year (QALY) gained. Results: A total of 330 participants were randomised to each group (total n = 660). Women randomised to LASH were more likely to be satisfied with their treatment than those randomised to EA (97.1% vs. 87.1%) [adjusted difference in proportions 0.10, 95% confidence interval (CI) 0.05 to 0.15; adjusted odds ratio (OR) from ordinal logistic regression (OLR) 2.53, 95% CI 1.83 to 3.48; p
- Published
- 2019
- Full Text
- View/download PDF
35. Sociology, Social Class, Health Inequalities, and the Avoidance of 'Classism'
- Author
-
Graham Scambler
- Subjects
social class ,health inequalities ,classism ,class/command dynamic ,institutional taming ,foresight and action sociology ,Sociology (General) ,HM401-1281 - Published
- 2019
- Full Text
- View/download PDF
36. Abstract 50: Occlusal & Dental Outcomes Following Facial Allotransplantation
- Author
-
Demetrius M. Coombs, MD, Fatma B. Tuncer, MD, Bahar B. Gharb, MD, PhD, Risal Djohan, MD, Brian Gastman, MD, Steven Bernard, MD, Mark F. Hendrickson, MD, Graham Schwarz, MD, Raffi Gurunian, MD, PhD, Maria Siemionow, MD, PhD, Francis Papay, MD, and Antonio Rampazzo, MD, PhD
- Subjects
Surgery ,RD1-811 - Published
- 2020
- Full Text
- View/download PDF
37. Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation
- Author
-
Graham Scotland, Moira Cruickshank, Elisabet Jacobsen, David Cooper, Cynthia Fraser, Michal Shimonovich, Angharad Marks, and Miriam Brazzelli
- Subjects
chronic kidney disease ,dialysis ,multiple-frequency bioimpedance devices ,cost-effectiveness ,Medical technology ,R855-855.5 - Abstract
Background: Chronic kidney disease (CKD) is a long-term condition requiring treatment such as conservative management, kidney transplantation or dialysis. To optimise the volume of fluid removed during dialysis (to avoid underhydration or overhydration), people are assigned a ‘target weight’, which is commonly assessed using clinical methods, such as weight gain between dialysis sessions, pre- and post-dialysis blood pressure and patient-reported symptoms. However, these methods are not precise, and measurement devices based on bioimpedance technology are increasingly used in dialysis centres. Current evidence on the role of bioimpedance devices for fluid management in people with CKD receiving dialysis is limited. Objectives: To evaluate the clinical effectiveness and cost-effectiveness of multiple-frequency bioimpedance devices versus standard clinical assessment for fluid management in people with CKD receiving dialysis. Data sources: We searched major electronic databases [e.g. MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index and Cochrane Central Register of Controlled Trials (CENTRAL)] conference abstracts and ongoing studies. There were no date restrictions. Searches were undertaken between June and October 2016. Review methods: Evidence was considered from randomised controlled trials (RCTs) comparing fluid management by multiple-frequency bioimpedance devices and standard clinical assessment in people receiving dialysis, and non-randomised studies evaluating the use of the devices for fluid management in people receiving dialysis. One reviewer extracted data and assessed the risk of bias of included studies. A second reviewer cross-checked the extracted data. Standard meta-analyses techniques were used to combine results from included studies. A Markov model was developed to assess the cost-effectiveness of the interventions. Results: Five RCTs (with 904 adult participants) and eight non-randomised studies (with 4915 adult participants) assessing the use of the Body Composition Monitor [(BCM) Fresenius Medical Care, Bad Homburg vor der Höhe, Germany] were included. Both absolute overhydration and relative overhydration were significantly lower in patients evaluated using BCM measurements than for those evaluated using standard clinical methods [weighted mean difference –0.44, 95% confidence interval (CI) –0.72 to –0.15, p = 0.003, I2 = 49%; and weighted mean difference –1.84, 95% CI –3.65 to –0.03; p = 0.05, I2 = 52%, respectively]. Pooled effects of bioimpedance monitoring on systolic blood pressure (SBP) (mean difference –2.46 mmHg, 95% CI –5.07 to 0.15 mmHg; p = 0.06, I2 = 0%), arterial stiffness (mean difference –1.18, 95% CI –3.14 to 0.78; p = 0.24, I2 = 92%) and mortality (hazard ratio = 0.689, 95% CI 0.23 to 2.08; p = 0.51) were not statistically significant. The economic evaluation showed that, when dialysis costs were included in the model, the probability of bioimpedance monitoring being cost-effective ranged from 13% to 26% at a willingness-to-pay threshold of £20,000 per quality-adjusted life-year gained. With dialysis costs excluded, the corresponding probabilities of cost-effectiveness ranged from 61% to 67%. Limitations: Lack of evidence on clinically relevant outcomes, children receiving dialysis, and any multifrequency bioimpedance devices, other than the BCM. Conclusions: BCM used in addition to clinical assessment may lower overhydration and potentially improve intermediate outcomes, such as SBP, but effects on mortality have not been demonstrated. If dialysis costs are not considered, the incremental cost-effectiveness ratio falls below £20,000, with modest effects on mortality and/or hospitalisation rates. The current findings are not generalisable to paediatric populations nor across other multifrequency bioimpedance devices. Future work: Services that routinely use the BCM should report clinically relevant intermediate and long-term outcomes before and after introduction of the device to extend the current evidence base. Study registration: This study is registered as PROSPERO CRD42016041785. Funding: The National Institute for Health Research Health Technology Assessment programme.
- Published
- 2018
- Full Text
- View/download PDF
38. Abstract QS50: Dermal Lymphatic Backflow Pattern in Rat Hind Limb Chronic Lymphatic Dysfunction Model
- Author
-
Vahe Fahradyan, MD, Edoardo Dalla Pozza, MD, Grzegorz Kwiecien, MD, Cagri Cakmakoglu, MD, Maria Madajka, PhD, Charlie Androjna, PhD, James Zins, MD, Bahar Bassiri Gharb, MD, PhD, and Graham Schwarz, MD
- Subjects
Surgery ,RD1-811 - Published
- 2018
- Full Text
- View/download PDF
39. Carabelli Trait in Australian Twins: Reliability and Validity of Different Scoring Systems
- Author
-
Yuh Hasegawa, James Rogers, Graham Scriven, and Grant Townsend
- Subjects
Dentistry ,RK1-715 ,Physical anthropology. Somatology ,GN49-298 - Abstract
We assessed the intra- and inter-observer reliability of two methods of scoring or categorizing Carabelli trait in both primary and permanent dentitions (Hanihara, 1961; Dahlberg, 1963). By using dental casts obtained from twins, we also compared the expression of Carabelli trait within and between monozygotic (MZ) co-twins to clarify the ontogenetic processes leading to different forms of trait expression. While intra-observer concordance rates were generally good (70 - 90%), inter-observer concordance rates were poor (35 - 60%). This indicates that considerable caution is needed when comparing data for Carabelli trait derived from different samples by different researchers. By comparing categories or scores for Carabelli trait in both dentitions of MZ co-twins, we found inter-relationships between groove and cuspal forms of the feature. Although the Arizona State University system developed by Turner is commonly used nowadays to score the Carabelli trait, we would encourage researchers interested in clarifying genetic influences and ontogenetic processes in both dentitions to refer to the often over-looked plaque of Hanihara and also Dahlberg’s plaque P12B. This should improve the reliability and validity of data obtained by helping to clarify the inter-relationships between the different phenotypic expressions of Carabelli trait.
- Published
- 2010
- Full Text
- View/download PDF
40. Erratum: An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation
- Author
-
Joanna Wardlaw, Miriam Brazzelli, Hector Miranda, Francesca Chappell, Paul McNamee, Graham Scotland, Zahid Quayyum, Duncan Martin, Kirsten Shuler, Peter Sandercock, and Martin Dennis
- Subjects
Medical technology ,R855-855.5 - Published
- 2015
- Full Text
- View/download PDF
41. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation
- Author
-
Pawana Sharma, Graham Scotland, Moira Cruickshank, Emma Tassie, Cynthia Fraser, Chris Burton, Bernard Croal, Craig R Ramsay, and Miriam Brazzelli
- Subjects
vitamin k antagonist therapy ,point-of-care tests ,coagulation ,systematic review ,economic evaluation ,clinical effectiveness ,cost-effectiveness ,patient self-monitoring ,Medical technology ,R855-855.5 - Abstract
Background: Self-monitoring (self-testing and self-management) could be a valid option for oral anticoagulation therapy monitoring in the NHS, but current evidence on its clinical effectiveness or cost-effectiveness is limited. Objectives: We investigated the clinical effectiveness and cost-effectiveness of point-of-care coagulometers for the self-monitoring of coagulation status in people receiving long-term vitamin K antagonist therapy, compared with standard clinic monitoring. Data sources: We searched major electronic databases (e.g. MEDLINE, MEDLINE In Process & Other Non-Indexed Citations, EMBASE, Bioscience Information Service, Science Citation Index and Cochrane Central Register of Controlled Trials) from 2007 to May 2013. Reports published before 2007 were identified from the existing Cochrane review (major databases searched from inception to 2007). The economic model parameters were derived from the clinical effectiveness review, other relevant reviews, routine sources of cost data and clinical experts’ advice. Review methods: We assessed randomised controlled trials (RCTs) evaluating self-monitoring in people with atrial fibrillation or heart valve disease requiring long-term anticoagulation therapy. CoaguChek® XS and S models (Roche Diagnostics, Basel, Switzerland), INRatio2® PT/INR monitor (Alere Inc., San Diego, CA USA), and ProTime Microcoagulation system® (International Technidyne Corporation, Nexus Dx, Edison, NJ, USA) coagulometers were compared with standard monitoring. Where possible, we combined data from included trials using standard inverse variance methods. Risk of bias assessment was performed using the Cochrane risk of bias tool. A de novo economic model was developed to assess the cost-effectiveness over a 10-year period. Results: We identified 26 RCTs (published in 45 papers) with a total of 8763 participants. CoaguChek was used in 85% of the trials. Primary analyses were based on data from 21 out of 26 trials. Only four trials were at low risk of bias. Major clinical events: self-monitoring was significantly better than standard monitoring in preventing thromboembolic events [relative risk (RR) 0.58, 95% confidence interval (CI) 0.40 to 0.84; p = 0.004]. In people with artificial heart valves (AHVs), self-monitoring almost halved the risk of thromboembolic events (RR 0.56, 95% CI 0.38 to 0.82; p = 0.003) and all-cause mortality (RR 0.54, 95% CI 0.32 to 0.92; p = 0.02). There was greater reduction in thromboembolic events and all-cause mortality through self-management but not through self-testing. Intermediate outcomes: self-testing, but not self-management, showed a modest but significantly higher percentage of time in therapeutic range, compared with standard care (weighted mean difference 4.44, 95% CI 1.71 to 7.18; p = 0.02). Patient-reported outcomes: improvements in patients’ quality of life related to self-monitoring were observed in six out of nine trials. High preference rates were reported for self-monitoring (77% to 98% in four trials). Net health and social care costs over 10 years were £7295 (self-monitoring with INRatio2); £7324 (standard care monitoring); £7333 (self-monitoring with CoaguChek XS) and £8609 (self-monitoring with ProTime). The estimated quality-adjusted life-year (QALY) gain associated with self-monitoring was 0.03. Self-monitoring with INRatio2 or CoaguChek XS was found to have ≈ 80% chance of being cost-effective, compared with standard monitoring at a willingness-to-pay threshold of £20,000 per QALY gained. Conclusions: Compared with standard monitoring, self-monitoring appears to be safe and effective, especially for people with AHVs. Self-monitoring, and in particular self-management, of anticoagulation status appeared cost-effective when pooled estimates of clinical effectiveness were applied. However, if self-monitoring does not result in significant reductions in thromboembolic events, it is unlikely to be cost-effective, based on a comparison of annual monitoring costs alone. Trials investigating the longer-term outcomes of self-management are needed, as well as direct comparisons of the various point-of-care coagulometers. Study registration: This study is registered as PROSPERO CRD42013004944. Funding: The National Institute for Health Research Health Technology Assessment programme.
- Published
- 2015
- Full Text
- View/download PDF
42. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial
- Author
-
Julie Brittenden, Seonaidh C Cotton, Andrew Elders, Emma Tassie, Graham Scotland, Craig R Ramsay, John Norrie, Jennifer Burr, Jill Francis, Samantha Wileman, Bruce Campbell, Paul Bachoo, Ian Chetter, Michael Gough, Jonothan Earnshaw, Tim Lees, Julian Scott, Sara A Baker, Graeme MacLennan, Maria Prior, Denise Bolsover, and Marion K Campbell
- Subjects
randomised controlled trial ,varicose veins ,endovenous laser ablation ,foam sclerotherapy ,surgery ,class ,bravvo ,Medical technology ,R855-855.5 - Abstract
Background: Foam sclerotherapy (foam) and endovenous laser ablation (EVLA) have emerged as alternative treatments to surgery for patients with varicose veins, but uncertainty exists regarding their effectiveness in the medium to longer term. Objectives: To assess the clinical effectiveness and cost-effectiveness of foam, EVLA and surgery for the treatment of varicose veins. Design: A parallel-group randomised controlled trial (RCT) without blinding, and economic modelling evaluation. Setting: Eleven UK specialist vascular centres. Participants: Seven hundred and ninety-eight patients with primary varicose veins (foam, n = 292; surgery, n = 294; EVLA, n = 212). Interventions: Patients were randomised between all three treatment options (eight centres) or between foam and surgery (three centres). Primary outcome measures: Disease-specific [Aberdeen Varicose Vein Questionnaire (AVVQ)] and generic [European Quality of Life-5 Dimensions (EQ-5D), Short Form questionnaire-36 items (SF-36) physical and mental component scores] quality of life (QoL) at 6 months. Cost-effectiveness as cost per quality-adjusted life-year (QALY) gained. Secondary outcome measures: Quality of life at 6 weeks; residual varicose veins; Venous Clinical Severity Score (VCSS); complication rates; return to normal activity; truncal vein ablation rates; and costs. Results: The results appear generalisable in that participants’ baseline characteristics (apart from a lower-than-expected proportion of females) and post-treatment improvement in outcomes were comparable with those in other RCTs. The health gain achieved in the AVVQ with foam was significantly lower than with surgery at 6 months [effect size −1.74, 95% confidence interval (CI) −2.97 to −0.50; p = 0.006], but was similar to that achieved with EVLA. The health gain in SF-36 mental component score for foam was worse than that for EVLA (effect size 1.54, 95% CI 0.01 to 3.06; p = 0.048) but similar to that for surgery. There were no differences in EQ-5D or SF-36 component scores in the surgery versus foam or surgery versus EVLA comparisons at 6 months.: The trial-based cost-effectiveness analysis showed that, at 6 months, foam had the highest probability of being considered cost-effective at a ceiling willingness-to-pay ratio of £20,000 per QALY. EVLA was found to cost £26,107 per QALY gained versus foam, and was less costly and generated slightly more QALYs than surgery. Markov modelling using trial costs and the limited recurrence data available suggested that, at 5 years, EVLA had the highest probability (≈ 79%) of being cost-effective at conventional thresholds, followed by foam (≈ 17%) and surgery (≈ 5%).: With regard to secondary outcomes, health gains at 6 weeks (p
- Published
- 2015
- Full Text
- View/download PDF
43. Cellular and viral peptides bind multiple sites on the N-terminal domain of clathrin
- Author
-
Muenzner, J, Traub, LM, Kelly, BT, and Graham, SC
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,arrestin ,assembly polypeptide 2 (AP2) ,endocytosis ,clathrin-mediated endocytosis ,hepatitis D virus ,amphiphysin ,3. Good health - Abstract
Short peptide motifs in unstructured regions of clathrin-adaptor proteins recruit clathrin to membranes to facilitate post-Golgi membrane transport. Three consensus clathrin-binding peptide sequences have been identified and structural studies show that each binds distinct sites on the clathrin heavy chain N-terminal domain (NTD). A fourth binding site for adaptors on NTD has been functionally identified but not structurally characterised. We have solved high resolution structures of NTD bound to peptide motifs from the cellular clathrin adaptors β2 adaptin and amphiphysin plus a putative viral clathrin adaptor, hepatitis D virus large antigen (HDAg-L). Surprisingly, with each peptide we observe simultaneous peptide binding at multiple sites on NTD and viral peptides binding to the same sites as cellular peptides. Peptides containing clathrin-box motifs (CBMs) with the consensus sequence LΦxΦ[DE] bind at the 'arrestin box' on NTD, between β-propeller blades 4 and 5, which had previously been thought to bind a distinct consensus sequence. Further, we structurally define the fourth peptide binding site on NTD, which we term the Royle box. In vitro binding assays show that clathrin is more readily captured by cellular CBMs than by HDAg-L, and site-directed mutagenesis confirms that multiple binding sites on NTD contribute to efficient capture by CBM peptides.
44. Dual Function of the pUL7-pUL51 Tegument Protein Complex in Herpes Simplex Virus 1 Infection
- Author
-
Albecka, A, Owen, DJ, Ivanova, L, Brun, J, Liman, R, Davies, L, Ahmed, MF, Colaco, S, Hollinshead, M, Graham, SC, and Crump, CM
- Subjects
human herpesviruses ,UL7 ,tegument ,viruses ,UL51 ,focal adhesion ,herpes simplex virus ,3. Good health - Abstract
The tegument of herpesviruses is a highly complex structural layer between the nucleocapsid and the envelope of virions. Tegument proteins play both structural and regulatory functions during replication and spread, but the interactions and functions of many of these proteins are poorly understood. Here we focus on two tegument proteins from herpes simplex virus 1 (HSV-1), pUL7 and pUL51, which have homologues in all other herpesviruses. We have now identified that HSV-1 pUL7 and pUL51 form a stable and direct protein-protein interaction, their expression levels rely on the presence of each other, and they function as a complex in infected cells. We demonstrate that expression of the pUL7-pUL51 complex is important for efficient HSV-1 assembly and plaque formation. Furthermore, we also discovered that the pUL7-pUL51 complex localizes to focal adhesions at the plasma membrane in both infected cells and in the absence of other viral proteins. The expression of pUL7-pUL51 is important to stabilize focal adhesions and maintain cell morphology in infected cells and cells infected with viruses lacking pUL7 and/or pUL51 round up more rapidly than cells infected with wild-type HSV-1. Our data suggest that, in addition to the previously reported functions in virus assembly and spread for pUL51, the pUL7-pUL51 complex is important for maintaining the attachment of infected cells to their surroundings through modulating the activity of focal adhesion complexes. $\textbf{IMPORTANCE}$: The $\textit{Herpesviridae }$ is a large family of highly successful human and animal pathogens. Virions of these viruses are composed of many different proteins, most of which are contained within the tegument, a complex structural layer between the nucleocapsid and the envelope within virus particles. Tegument proteins have important roles in assembling virus particles as well as modifying host cells to promote virus replication and spread. However, little is known about the function of many tegument proteins during virus replication. Our study focuses on two tegument proteins from herpes simplex virus 1 that are conserved in all herpesviruses: pUL7 and pUL51. We demonstrate that these proteins directly interact and form a functional complex that is important for both virus assembly and modulation of host cell morphology. Further, we identify for the first time that these conserved herpesvirus tegument proteins localize to focal adhesions in addition to cytoplasmic juxtanuclear membranes within infected cells.
45. A conserved interaction between a C-terminal motif in Norovirus VPg and the HEAT-1 domain of eIF4G is essential for translation initiation
- Author
-
Curry, S, Leen, EN, Sorgeloos, F, Correia, S, Chaudhry, Y, Cannac, F, Pastore, C, Xu, Y, Graham, SC, Matthews, SJ, and Goodfellow, IG
- Subjects
viruses ,food and beverages ,environment and public health ,3. Good health - Abstract
Translation initiation is a critical early step in the replication cycle of the positive-sense, single-stranded RNA genome of noroviruses, a major cause of gastroenteritis in humans. Norovirus RNA, which has neither a 5 ́ m7G cap nor an internal ribosome entry site (IRES), adopts an unusual mechanism to initiate protein synthesis that relies on interactions between the VPg protein covalently attached to the 5 ́-end of the viral RNA and eukaryotic initiation factors (eIFs) in the host cell. For murine norovirus (MNV) we previously showed that VPg binds to the middle fragment of eIF4G (4GM; residues 652-1132). Here we have used pull-down assays, fluorescence anisotropy, and isothermal titration calorimetry (ITC) to demonstrate that a stretch of ~20 amino acids at the C terminus of MNV VPg mediates direct and specific binding to the HEAT-1 domain within the 4GM fragment of eIF4G. Our analysis further reveals that the MNV C-terminus binds to eIF4G HEAT-1 via a motif that is conserved in all known noroviruses. Fine mutagenic mapping suggests that the MNV VPg C terminus may interact with eIF4G in a helical conformation. NMR spectroscopy was used to define the VPg binding site on eIF4G HEAT-1, which was confirmed by mutagenesis and binding assays. We have found that this site is non-overlapping with the binding site for eIF4A on eIF4G HEAT-1 by demonstrating that norovirus VPg can form ternary VPg-eIF4G-eIF4A complexes. The functional significance of the VPg-eIF4G interaction was shown by the ability of fusion proteins containing the C- terminal peptide of MNV VPg to inhibit translation of norovirus RNA but not cap- or IRES-dependent translation. These observations define important structural details of a functional interaction between norovirus VPg and eIF4G and reveal a binding interface that might be exploited as a target for antiviral therapy.
46. An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation
- Author
-
Joanna Wardlaw, Miriam Brazzelli, Hector Miranda, Francesca Chappell, Paul McNamee, Graham Scotland, Zahid Quayyum, Duncan Martin, Kirsten Shuler, Peter Sandercock, and Martin Dennis
- Subjects
assessment ,cost-effectiveness ,magnetic resonance, diffusion-weighted imaging ,transient ischaemic attack ,minor stroke ,systematic review ,meta-analysis ,economic evaluation ,Medical technology ,R855-855.5 - Abstract
Background: Patients with transient ischaemic attack (TIA) or minor stroke need rapid treatment of risk factors to prevent recurrent stroke. ABCD2 score or magnetic resonance diffusion-weighted brain imaging (MR DWI) may help assessment and treatment. Objectives: Is MR with DWI cost-effective in stroke prevention compared with computed tomography (CT) brain scanning in all patients, in specific subgroups or as ‘one-stop’ brain-carotid imaging? What is the current UK availability of services for stroke prevention? Data sources: Published literature; stroke registries, audit and randomised clinical trials; national databases; survey of UK clinical and imaging services for stroke; expert opinion. Review methods: Systematic reviews and meta-analyses of published/unpublished data. Decision-analytic model of stroke prevention including on a 20-year time horizon including nine representative imaging scenarios. Results: The pooled recurrent stroke rate after TIA (53 studies, 30,558 patients) is 5.2% [95% confidence interval (CI) 3.9% to 5.9%] by 7 days, and 6.7% (5.2% to 8.7%) at 90 days. ABCD2 score does not identify patients with key stroke causes or identify mimics: 66% of specialist-diagnosed true TIAs and 35–41% of mimics had an ABCD2 score of ≥ 4; 20% of true TIAs with ABCD2 score of 1 week after symptoms to diagnose haemorrhage; strategies that triaged patients with low ABCD2 scores for slow investigation or treated DWI-negative patients as non-TIA/minor stroke prevented fewer strokes and increased costs. ‘One-stop’ CT/MR angiographic-plus-brain imaging was not cost-effective. Limitations: Data on sensitivity/specificity of MR in TIA/minor stroke, stroke costs, prognosis of TIA mimics and accuracy of ABCD2 score by non-specialists are sparse or absent; all analysis had substantial heterogeneity. Conclusions: Magnetic resonance with DWI is not cost-effective for secondary stroke prevention. MR was most helpful in patients presenting at > 1 week after symptoms if blood-sensitive sequences were used. ABCD2 score is unlikely to facilitate patient triage by non-stroke specialists. Rapid specialist assessment, CT brain scanning and identification of serious underlying stroke causes is the most cost-effective stroke prevention strategy. Funding: The National Institute for Health Research Health Technology Assessment programme.
- Published
- 2014
- Full Text
- View/download PDF
47. Immediate auditory repetition of words and nonwords: an ERP study of lexical and sublexical processing.
- Author
-
Xiaorong Cheng, Graham Schafer, and Patricia M Riddell
- Subjects
Medicine ,Science - Abstract
ERPs were elicited to (1) words, (2) pseudowords derived from these words, and (3) nonwords with no lexical neighbors, in a task involving listening to immediately repeated auditory stimuli. There was a significant early (P200) effect of phonotactic probability in the first auditory presentation, which discriminated words and pseudowords from nonwords; and a significant somewhat later (N400) effect of lexicality, which discriminated words from pseudowords and nonwords. There was no reliable effect of lexicality in the ERPs to the second auditory presentation. We conclude that early sublexical phonological processing differed according to phonotactic probability of the stimuli, and that lexically-based redintegration occurred for words but did not occur for pseudowords or nonwords. Thus, in online word recognition and immediate retrieval, phonological and/or sublexical processing plays a more important role than lexical level redintegration.
- Published
- 2014
- Full Text
- View/download PDF
48. The Female Sex Work Industry in a District of India in the Context of HIV Prevention
- Author
-
Raluca Buzdugan, Shiva S. Halli, Jyoti M. Hiremath, Krishnamurthy Jayanna, T. Raghavendra, Stephen Moses, James Blanchard, Graham Scambler, and Frances Cowan
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
HIV prevalence in India remains high among female sex workers. This paper presents the main findings of a qualitative study of the modes of operation of female sex work in Belgaum district, Karnataka, India, incorporating fifty interviews with sex workers. Thirteen sex work settings (distinguished by sex workers' main places of solicitation and sex) are identified. In addition to previously documented brothel, lodge, street, dhaba (highway restaurant), and highway-based sex workers, under-researched or newly emerging sex worker categories are identified, including phone-based sex workers, parlour girls, and agricultural workers. Women working in brothels, lodges, dhabas, and on highways describe factors that put them at high HIV risk. Of these, dhaba and highway-based sex workers are poorly covered by existing interventions. The paper examines the HIV-related vulnerability factors specific to each sex work setting. The modes of operation and HIV-vulnerabilities of sex work settings identified in this paper have important implications for the local programme.
- Published
- 2012
- Full Text
- View/download PDF
49. Human cytomegalovirus deploys molecular mimicry to recruit VPS4A to sites of virus assembly.
- Author
-
Butt BG, Fischer D, Rep AR, Schauflinger M, Read C, Böck T, Hirner M, Wienen F, Graham SC, and von Einem J
- Subjects
- Humans, Cytomegalovirus Infections virology, Cytomegalovirus Infections metabolism, ATPases Associated with Diverse Cellular Activities metabolism, ATPases Associated with Diverse Cellular Activities genetics, Viral Proteins metabolism, Viral Proteins genetics, Endosomal Sorting Complexes Required for Transport metabolism, Vacuolar Proton-Translocating ATPases metabolism, Vacuolar Proton-Translocating ATPases genetics, Cytomegalovirus metabolism, Cytomegalovirus genetics, Cytomegalovirus physiology, Virus Assembly physiology, Molecular Mimicry
- Abstract
The AAA-type ATPase VPS4 is recruited by proteins of the endosomal sorting complex required for transport III (ESCRT-III) to catalyse membrane constriction and membrane fission. VPS4A accumulates at the cytoplasmic viral assembly complex (cVAC) of cells infected with human cytomegalovirus (HCMV), the site where nascent virus particles obtain their membrane envelope. Here we show that VPS4A is recruited to the cVAC via interaction with pUL71. Sequence analysis, deep-learning structure prediction, molecular dynamics and mutagenic analysis identify a short peptide motif in the C-terminal region of pUL71 that is necessary and sufficient for the interaction with VPS4A. This motif is predicted to bind the same groove of the N-terminal VPS4A Microtubule-Interacting and Trafficking (MIT) domain as the Type 2 MIT-Interacting Motif (MIM2) of cellular ESCRT-III components, and this viral MIM2-like motif (vMIM2) is conserved across β-herpesvirus pUL71 homologues. However, recruitment of VPS4A by pUL71 is dispensable for HCMV morphogenesis or replication and the function of the conserved vMIM2 during infection remains enigmatic. VPS4-recruitment via a vMIM2 represents a previously unknown mechanism of molecular mimicry in viruses, extending previous observations that herpesviruses encode proteins with structural and functional homology to cellular ESCRT-III components., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Butt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
50. Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins.
- Author
-
Schmitt J, Poole E, Groves I, Owen DJ, Graham SC, Sinclair J, and Kelly BT
- Subjects
- Humans, Proprotein Convertases metabolism, Membrane Proteins, Receptors, LDL metabolism, Proprotein Convertase 9 metabolism, Serine Endopeptidases
- Abstract
The exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). Recombinant antibodies genetically fused to this domain drive the degradation of membrane proteins that undergo constitutive internalisation and recycling, including the transferrin receptor and the human cytomegalovirus latency-associated protein US28. We term this approach PACTAC (PCSK9-Antibody Clearance-Targeting Chimeras)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.